Example logo GIS 26

Global Innovation Summit 2026

6 May 2026 | Basel, Switzerland

Home
Register
Register
Register

Frances Lasowski

CEO

20/20 OptimEyes Technologies

Hamilton, Canada

Frances Lasowski is the CEO of 20/20 OptimEyes Technologies, developing a mucoadhesive nanoparticle platform that enables sustained, localized drug delivery across mucosal tissues. She brings deep expertise in polymer engineering and drug delivery.

My organisation

20/20 OptimEyes Technologies has developed a mucoadhesive nanoparticle (MNP) drug delivery platform that enhances API solubility and significantly improves the durability of drug exposure at mucosal surfaces. The company is actively advancing and partnering the platform across multiple therapeutic areas, with active programs in ophthalmology, respiratory infections, and bladder oncology, and is seeking both strategic partnerships and investment to accelerate development and maximize platform value. The technology has been validated in ophthalmic applications, with successful preclinical studies in glaucoma, dry eye, and uveitis, demonstrating its ability to improve efficacy, patient compliance, and lifecycle potential of small-molecule therapeutics. 20/20 OptimEyes is engaging partners for co-development, licensing, and application of the platform to novel or repurposed APIs targeting mucosal tissues.
Read more

About me

I’m a polymer scientist and CEO of 20/20 OptimEyes Technologies, where we’re advancing a mucoadhesive nanoparticle platform designed to improve how drugs are delivered across mucosal surfaces. My background is in chemical and biomedical engineering, with a focus on translating materials science into practical therapeutic solutions.

My work sits at the intersection of formulation science, drug delivery, and product development. I’m particularly interested in approaches that can meaningfully improve patient adherence and outcomes without requiring entirely new drugs.

I’m looking to connect with partners who see the value of enabling technologies and are interested in applying them across multiple indications — from ophthalmology to broader mucosal delivery opportunities.

Social media